Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

1997-2010

ABSTRACT

This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there are sites where anti-HIV drugs cannot penetrate enough to stop new HIV replication; and 3) if HIV in certain lymph nodes can remain infectious for prolonged periods of time. It will also explore whether immune system damage caused by HIV can be repaired after new virus replication is stopped with treatment.HIV-infected patients 18 years of age and older may be eligible for this study, which will include three groups as follows. Candidates will be screened with a medical history, physical examination, blood and urine tests and possibly chest X-ray and electrocardiogram.Participants will be divided into three groups according to CD4 count levels: > 500 cells/microliter of blood; between 300 and 500 cells/microliter, and < 300 cells/microliter of blood. All participants will be treated with a combination of four antiretroviral drugs: indinavir, zidovudine, lamivudine and nevirapine. (Exceptions to this regimen may be made in certain circumstances for patients who cannot tolerate one of the four drugs.) In addition, they will undergo the following procedures:Blood tests - Blood tests will be done at screening and at study entry to evaluate the patient's health status and measure CD4 T cell count and plasma HIV levels; at the beginning of treatment to look for drug-related side effects; and during the course of the study to evaluate drug effectiveness in inhibiting HIV replication; CD4 T cell levels and function.Lymph node biopsy - Lymph node biopsies are done under local anesthesia. A small incision is made, the node is removed, and the incision is closed with stitches. Up to two nodes may be removed during each procedure. Patients with CD4 counts greater than 500 cells/microliter of blood and those with counts less than 300 cells/microliter will have three lymph node biopsies in order to 1) assess the effectiveness of therapy in inhibiting HIV replication in the nodes (the major site of replication); 2) determine how long HIV-infected cells may persist in the nodes after new replication is stopped by therapy; and 3) determine if immune damage caused by HIV can be repaired when virus replication is stopped. Lymph node biopsy in patients with counts between 300 and 500 cells/microliter of blood is required only at baseline, although follow-up biopsies are encouraged.Leukapheresis - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a cell separator machine where the white cells are removed and collected. The rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm. The collected white cells are used for special studies of the level and function of T cells before and after drug treatment. Patients with CD4 counts > 500 cells/microliter and < 300 cells/microliter will undergo leukapheresis up to four times - at study entry and about 2, 6 and 12 months after starting antiretroviral therapy. Patients with CD4 counts between 300 and 500 cells/microliter will have this procedure either at study entry and 6 and 12 weeks after initiation therapy, or on the same schedule as the other patients. Detailed Description The reservoirs of HIV-1 infection that permit maintenance of persistent virus infection (even when virus replication cannot be detected using sensitive assays to quantify plasma HIV-1 RNA levels) are currently unknown. Potential sites for persistent HIV-1 infection include cells with chronic or latent infections, cells present in locations within the body where antiviral drugs may not penetrate in levels sufficient to prevent additional cycles of de novo virus infection (e.g., the central nervous system), the presence of susceptible target cells for virus infection that may not metabolize certain antiviral drugs to their active inhibitory forms (e.g., macrophages), or extracellular (possible infectious) virus that may be retained on the surface of follicular dendritic cells within lymphoid organs. In an attempt to determine which, if any, of these potential reservoirs contribute to persistent HIV-1 infection, HIV-1-infected persons in two groups categorized by CD4+ T cell levels will be treated with concomitant administration of 4 antiviral drugs (zidovudine, lamivudine, indinavir and nevirapine) to accomplish maximal achievable suppression of virus replication. The rates of decay of virus and virus-infected cells following initiation of antiviral (and steroid) therapy will be monitored with sensitive, quantitative assays, and the identity and longevity of persistent sites of infection will be determined. This study may also illuminate to what extent HIV-1-induced immune system damage manifest as decreased CD4 T cell responses, a constricted repertoire of T cell antigen recognition, or as structural compromise of lymphoid tissue architecture can be reversed upon cessation of active HIV-1 replication by combinations of potent antiviral drugs. More... »

URL

https://clinicaltrials.gov/show/NCT00001644

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there are sites where anti-HIV drugs cannot penetrate enough to stop new HIV replication; and 3) if HIV in certain lymph nodes can remain infectious for prolonged periods of time. It will also explore whether immune system damage caused by HIV can be repaired after new virus replication is stopped with treatment.HIV-infected patients 18 years of age and older may be eligible for this study, which will include three groups as follows. Candidates will be screened with a medical history, physical examination, blood and urine tests and possibly chest X-ray and electrocardiogram.Participants will be divided into three groups according to CD4 count levels: > 500 cells/microliter of blood; between 300 and 500 cells/microliter, and < 300 cells/microliter of blood. All participants will be treated with a combination of four antiretroviral drugs: indinavir, zidovudine, lamivudine and nevirapine. (Exceptions to this regimen may be made in certain circumstances for patients who cannot tolerate one of the four drugs.) In addition, they will undergo the following procedures:Blood tests - Blood tests will be done at screening and at study entry to evaluate the patient's health status and measure CD4 T cell count and plasma HIV levels; at the beginning of treatment to look for drug-related side effects; and during the course of the study to evaluate drug effectiveness in inhibiting HIV replication; CD4 T cell levels and function.Lymph node biopsy - Lymph node biopsies are done under local anesthesia. A small incision is made, the node is removed, and the incision is closed with stitches. Up to two nodes may be removed during each procedure. Patients with CD4 counts greater than 500 cells/microliter of blood and those with counts less than 300 cells/microliter will have three lymph node biopsies in order to 1) assess the effectiveness of therapy in inhibiting HIV replication in the nodes (the major site of replication); 2) determine how long HIV-infected cells may persist in the nodes after new replication is stopped by therapy; and 3) determine if immune damage caused by HIV can be repaired when virus replication is stopped. Lymph node biopsy in patients with counts between 300 and 500 cells/microliter of blood is required only at baseline, although follow-up biopsies are encouraged.Leukapheresis - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a cell separator machine where the white cells are removed and collected. The rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm. The collected white cells are used for special studies of the level and function of T cells before and after drug treatment. Patients with CD4 counts > 500 cells/microliter and < 300 cells/microliter will undergo leukapheresis up to four times - at study entry and about 2, 6 and 12 months after starting antiretroviral therapy. Patients with CD4 counts between 300 and 500 cells/microliter will have this procedure either at study entry and 6 and 12 weeks after initiation therapy, or on the same schedule as the other patients.\n\nDetailed Description\nThe reservoirs of HIV-1 infection that permit maintenance of persistent virus infection (even when virus replication cannot be detected using sensitive assays to quantify plasma HIV-1 RNA levels) are currently unknown. Potential sites for persistent HIV-1 infection include cells with chronic or latent infections, cells present in locations within the body where antiviral drugs may not penetrate in levels sufficient to prevent additional cycles of de novo virus infection (e.g., the central nervous system), the presence of susceptible target cells for virus infection that may not metabolize certain antiviral drugs to their active inhibitory forms (e.g., macrophages), or extracellular (possible infectious) virus that may be retained on the surface of follicular dendritic cells within lymphoid organs. In an attempt to determine which, if any, of these potential reservoirs contribute to persistent HIV-1 infection, HIV-1-infected persons in two groups categorized by CD4+ T cell levels will be treated with concomitant administration of 4 antiviral drugs (zidovudine, lamivudine, indinavir and nevirapine) to accomplish maximal achievable suppression of virus replication. The rates of decay of virus and virus-infected cells following initiation of antiviral (and steroid) therapy will be monitored with sensitive, quantitative assays, and the identity and longevity of persistent sites of infection will be determined. This study may also illuminate to what extent HIV-1-induced immune system damage manifest as decreased CD4 T cell responses, a constricted repertoire of T cell antigen recognition, or as structural compromise of lymphoid tissue architecture can be reversed upon cessation of active HIV-1 replication by combinations of potent antiviral drugs.", 
    "endDate": "2010-02", 
    "id": "sg:clinicaltrial.NCT00001644", 
    "keywords": [
      "HIV-1 infection", 
      "persistent HIV-1 infection", 
      "T cell levels", 
      "study entry", 
      "HIV replication", 
      "antiviral drugs", 
      "virus infection", 
      "virus replication", 
      "node biopsy", 
      "cells/", 
      "antiviral therapy", 
      "health status", 
      "de novo virus infection", 
      "active HIV-1 replication", 
      "HIV-1-infected persons", 
      "CD4 T-cell count", 
      "drug-related side effects", 
      "CD4 T cell responses", 
      "CD4 T-cell levels", 
      "white cells", 
      "certain lymph nodes", 
      "cell separator machines", 
      "patients 18 years", 
      "T-cell counts", 
      "combination antiviral therapy", 
      "lymph node biopsy", 
      "T cell responses", 
      "follicular dendritic cells", 
      "persistent virus infection", 
      "CD4 count levels", 
      "HIV-1 replication", 
      "effectiveness of therapy", 
      "beginning of treatment", 
      "susceptible target cells", 
      "patients' health status", 
      "potent antiviral drugs", 
      "lymphoid tissue architecture", 
      "immune system damage", 
      "T cell antigen recognition", 
      "virus-infected cells", 
      "antiretroviral therapy", 
      "HIV levels", 
      "HIV infection", 
      "initiation therapy", 
      "lymph nodes", 
      "concomitant administration", 
      "dendritic cells", 
      "arm vein", 
      "physical examination", 
      "immune damage", 
      "local anesthesia", 
      "antiretroviral drugs", 
      "urine tests", 
      "medical history", 
      "lymphoid organs", 
      "certain antiviral drugs", 
      "T cells", 
      "drug treatment", 
      "side effects", 
      "latent infection", 
      "HIV", 
      "small incision", 
      "cell level", 
      "HIV drugs", 
      "patients", 
      "same schedule", 
      "CD4", 
      "immune system", 
      "cell count", 
      "biopsy", 
      "therapy", 
      "cell responses", 
      "drug effectiveness", 
      "infection", 
      "persistent reservoir", 
      "blood", 
      "system damage", 
      "antigen recognition", 
      "target cells", 
      "whole blood", 
      "same needle", 
      "drugs", 
      "additional cycles", 
      "second needle", 
      "extracellular virus", 
      "lymph", 
      "leukapheresis", 
      "structural compromise", 
      "damage manifests", 
      "treatment", 
      "incision", 
      "active inhibitory form", 
      "prolonged period", 
      "count", 
      "inhibitory form", 
      "cells", 
      "virus", 
      "count levels", 
      "tissue architecture", 
      "potential reservoirs", 
      "group", 
      "quantitative assay", 
      "participants", 
      "needle", 
      "levels", 
      "lamivudine", 
      "zidovudine", 
      "anesthesia", 
      "chronic", 
      "nevirapine", 
      "replication", 
      "indinavir", 
      "follow", 
      "study", 
      "administration", 
      "baseline", 
      "damage", 
      "weeks", 
      "months", 
      "cessation", 
      "electrocardiogram", 
      "vein", 
      "age", 
      "procedure", 
      "period", 
      "entry", 
      "special study", 
      "organs", 
      "long period", 
      "examination", 
      "screening", 
      "body", 
      "stitches", 
      "status", 
      "test", 
      "assays", 
      "X-ray", 
      "potential sites", 
      "arm", 
      "initiation", 
      "suppression", 
      "years", 
      "longevity", 
      "persons", 
      "new replication", 
      "course", 
      "sites", 
      "response", 
      "combination", 
      "rest", 
      "function", 
      "nodes", 
      "time", 
      "schedule", 
      "history", 
      "manifest", 
      "effectiveness", 
      "repertoire", 
      "rate", 
      "effect", 
      "achievable suppression", 
      "maintenance", 
      "presence", 
      "use", 
      "candidates", 
      "persistent sites", 
      "compromise", 
      "rate of decay", 
      "addition", 
      "recognition", 
      "detailed description", 
      "attempt", 
      "beginning", 
      "determine", 
      "cycle", 
      "location", 
      "reservoir", 
      "form", 
      "system", 
      "order", 
      "description", 
      "identity", 
      "surface", 
      "decay", 
      "machine", 
      "architecture"
    ], 
    "name": "Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00001644"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2022-10-01T07:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/clinical_trial/clinical_trial_0.jsonl", 
    "sponsor": [
      {
        "id": "http://www.grid.ac/institutes/grid.419681.3", 
        "type": "Organization"
      }, 
      {
        "id": "http://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "1997-03", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/373123a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014949926", 
          "https://doi.org/10.1038/373123a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/373117a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025418642", 
          "https://doi.org/10.1038/373117a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00001644"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00001644'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00001644'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00001644'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00001644'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      16 PREDICATES      207 URIs      195 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00001644 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1107
4 anzsrc-for:1108
5 schema:description This study will try to define how and where HIV infection persists in the body by determining: 1) if there are cells where HIV can live for long periods of time without being seen and destroyed by the immune system; 2) if there are sites where anti-HIV drugs cannot penetrate enough to stop new HIV replication; and 3) if HIV in certain lymph nodes can remain infectious for prolonged periods of time. It will also explore whether immune system damage caused by HIV can be repaired after new virus replication is stopped with treatment.HIV-infected patients 18 years of age and older may be eligible for this study, which will include three groups as follows. Candidates will be screened with a medical history, physical examination, blood and urine tests and possibly chest X-ray and electrocardiogram.Participants will be divided into three groups according to CD4 count levels: > 500 cells/microliter of blood; between 300 and 500 cells/microliter, and < 300 cells/microliter of blood. All participants will be treated with a combination of four antiretroviral drugs: indinavir, zidovudine, lamivudine and nevirapine. (Exceptions to this regimen may be made in certain circumstances for patients who cannot tolerate one of the four drugs.) In addition, they will undergo the following procedures:Blood tests - Blood tests will be done at screening and at study entry to evaluate the patient's health status and measure CD4 T cell count and plasma HIV levels; at the beginning of treatment to look for drug-related side effects; and during the course of the study to evaluate drug effectiveness in inhibiting HIV replication; CD4 T cell levels and function.Lymph node biopsy - Lymph node biopsies are done under local anesthesia. A small incision is made, the node is removed, and the incision is closed with stitches. Up to two nodes may be removed during each procedure. Patients with CD4 counts greater than 500 cells/microliter of blood and those with counts less than 300 cells/microliter will have three lymph node biopsies in order to 1) assess the effectiveness of therapy in inhibiting HIV replication in the nodes (the major site of replication); 2) determine how long HIV-infected cells may persist in the nodes after new replication is stopped by therapy; and 3) determine if immune damage caused by HIV can be repaired when virus replication is stopped. Lymph node biopsy in patients with counts between 300 and 500 cells/microliter of blood is required only at baseline, although follow-up biopsies are encouraged.Leukapheresis - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a cell separator machine where the white cells are removed and collected. The rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm. The collected white cells are used for special studies of the level and function of T cells before and after drug treatment. Patients with CD4 counts > 500 cells/microliter and < 300 cells/microliter will undergo leukapheresis up to four times - at study entry and about 2, 6 and 12 months after starting antiretroviral therapy. Patients with CD4 counts between 300 and 500 cells/microliter will have this procedure either at study entry and 6 and 12 weeks after initiation therapy, or on the same schedule as the other patients. Detailed Description The reservoirs of HIV-1 infection that permit maintenance of persistent virus infection (even when virus replication cannot be detected using sensitive assays to quantify plasma HIV-1 RNA levels) are currently unknown. Potential sites for persistent HIV-1 infection include cells with chronic or latent infections, cells present in locations within the body where antiviral drugs may not penetrate in levels sufficient to prevent additional cycles of de novo virus infection (e.g., the central nervous system), the presence of susceptible target cells for virus infection that may not metabolize certain antiviral drugs to their active inhibitory forms (e.g., macrophages), or extracellular (possible infectious) virus that may be retained on the surface of follicular dendritic cells within lymphoid organs. In an attempt to determine which, if any, of these potential reservoirs contribute to persistent HIV-1 infection, HIV-1-infected persons in two groups categorized by CD4+ T cell levels will be treated with concomitant administration of 4 antiviral drugs (zidovudine, lamivudine, indinavir and nevirapine) to accomplish maximal achievable suppression of virus replication. The rates of decay of virus and virus-infected cells following initiation of antiviral (and steroid) therapy will be monitored with sensitive, quantitative assays, and the identity and longevity of persistent sites of infection will be determined. This study may also illuminate to what extent HIV-1-induced immune system damage manifest as decreased CD4 T cell responses, a constricted repertoire of T cell antigen recognition, or as structural compromise of lymphoid tissue architecture can be reversed upon cessation of active HIV-1 replication by combinations of potent antiviral drugs.
6 schema:endDate 2010-02
7 schema:keywords CD4
8 CD4 T cell responses
9 CD4 T-cell count
10 CD4 T-cell levels
11 CD4 count levels
12 HIV
13 HIV drugs
14 HIV infection
15 HIV levels
16 HIV replication
17 HIV-1 infection
18 HIV-1 replication
19 HIV-1-infected persons
20 T cell antigen recognition
21 T cell levels
22 T cell responses
23 T cells
24 T-cell counts
25 X-ray
26 achievable suppression
27 active HIV-1 replication
28 active inhibitory form
29 addition
30 additional cycles
31 administration
32 age
33 anesthesia
34 antigen recognition
35 antiretroviral drugs
36 antiretroviral therapy
37 antiviral drugs
38 antiviral therapy
39 architecture
40 arm
41 arm vein
42 assays
43 attempt
44 baseline
45 beginning
46 beginning of treatment
47 biopsy
48 blood
49 body
50 candidates
51 cell count
52 cell level
53 cell responses
54 cell separator machines
55 cells
56 cells/
57 certain antiviral drugs
58 certain lymph nodes
59 cessation
60 chronic
61 combination
62 combination antiviral therapy
63 compromise
64 concomitant administration
65 count
66 count levels
67 course
68 cycle
69 damage
70 damage manifests
71 de novo virus infection
72 decay
73 dendritic cells
74 description
75 detailed description
76 determine
77 drug effectiveness
78 drug treatment
79 drug-related side effects
80 drugs
81 effect
82 effectiveness
83 effectiveness of therapy
84 electrocardiogram
85 entry
86 examination
87 extracellular virus
88 follicular dendritic cells
89 follow
90 form
91 function
92 group
93 health status
94 history
95 identity
96 immune damage
97 immune system
98 immune system damage
99 incision
100 indinavir
101 infection
102 inhibitory form
103 initiation
104 initiation therapy
105 lamivudine
106 latent infection
107 leukapheresis
108 levels
109 local anesthesia
110 location
111 long period
112 longevity
113 lymph
114 lymph node biopsy
115 lymph nodes
116 lymphoid organs
117 lymphoid tissue architecture
118 machine
119 maintenance
120 manifest
121 medical history
122 months
123 needle
124 nevirapine
125 new replication
126 node biopsy
127 nodes
128 order
129 organs
130 participants
131 patients
132 patients 18 years
133 patients' health status
134 period
135 persistent HIV-1 infection
136 persistent reservoir
137 persistent sites
138 persistent virus infection
139 persons
140 physical examination
141 potent antiviral drugs
142 potential reservoirs
143 potential sites
144 presence
145 procedure
146 prolonged period
147 quantitative assay
148 rate
149 rate of decay
150 recognition
151 repertoire
152 replication
153 reservoir
154 response
155 rest
156 same needle
157 same schedule
158 schedule
159 screening
160 second needle
161 side effects
162 sites
163 small incision
164 special study
165 status
166 stitches
167 structural compromise
168 study
169 study entry
170 suppression
171 surface
172 susceptible target cells
173 system
174 system damage
175 target cells
176 test
177 therapy
178 time
179 tissue architecture
180 treatment
181 urine tests
182 use
183 vein
184 virus
185 virus infection
186 virus replication
187 virus-infected cells
188 weeks
189 white cells
190 whole blood
191 years
192 zidovudine
193 schema:name Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication
194 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00001644
195 schema:sdDatePublished 2022-10-01T07:01
196 schema:sdLicense https://scigraph.springernature.com/explorer/license/
197 schema:sdPublisher N97414ae886ff49efb3687f1091b14fb5
198 schema:sponsor grid-institutes:grid.410305.3
199 grid-institutes:grid.419681.3
200 schema:startDate 1997-03
201 schema:subjectOf sg:pub.10.1038/373117a0
202 sg:pub.10.1038/373123a0
203 schema:url https://clinicaltrials.gov/show/NCT00001644
204 sgo:license sg:explorer/license/
205 sgo:sdDataset clinical_trials
206 rdf:type schema:MedicalStudy
207 N97414ae886ff49efb3687f1091b14fb5 schema:name Springer Nature - SN SciGraph project
208 rdf:type schema:Organization
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
214 rdf:type schema:DefinedTerm
215 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
216 rdf:type schema:DefinedTerm
217 sg:pub.10.1038/373117a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025418642
218 https://doi.org/10.1038/373117a0
219 rdf:type schema:CreativeWork
220 sg:pub.10.1038/373123a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014949926
221 https://doi.org/10.1038/373123a0
222 rdf:type schema:CreativeWork
223 grid-institutes:grid.410305.3 schema:Organization
224 grid-institutes:grid.419681.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...